-
Mashup Score: 1Acalabrutinib, Alone or With Obinutuzumab, Improves Quality-Adjusted Survival in Frontline CLL - 3 year(s) ago
Treatment with acalabrutinib as monotherapy or in combination with obinutuzumab improved quality-adjusted survival compared with chlorambucil plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Liso-cel Plus Ibrutinib Demonstrates Tolerable Safety Profile in Relapsed/Refractory CLL/SLL - 3 year(s) ago
Lisocabtagene maraleucel in combination with ibrutinib was associated with manageable safety for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, according to updated data from the phase 1 TRANSCEND-CLL-004 trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1cfDNA-Based MRD Assessment Is Feasible, Yields Highly Concordant Results in Relapsed/Refractory CLL - 3 year(s) ago
The use of a cell-free DNA–based minimal residual disease assay demonstrated feasibility and highly concordant results compared with 4-color flow cytometry and improved MRD detection in patients with chronic lymphocytic leukemia who were treated with time-limited venetoclax, acalabrutinib, and obinutuzumab.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Interim analysis of the ALPINE study - 3 year(s) ago
Barbara Eichhorst, MD, of the University Hospital Cologne, Cologne, Germany, talks on the interim analysis of the Phase III ALPINE…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1cfDNA-Based MRD Assessment Is Feasible, Yields Highly Concordant Results in Relapsed/Refractory CLL - 3 year(s) ago
The use of a cell-free DNA–based minimal residual disease assay demonstrated feasibility and highly concordant results compared with 4-color flow cytometry and improved MRD detection in patients with chronic lymphocytic leukemia who were treated with time-limited venetoclax, acalabrutinib, and obinutuzumab.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
According to the CLL2-BAAG trial, the cfDNA-based method was identified as less expensive & quicker & can complement flow cytometry when the 2 are used in combination, to better improve MRD detection in this patient population. @iwCLL #iwCLL2021 #leusm https://t.co/FeFhSNJo17 https://t.co/qyXUyeIxyP
-
-
Mashup Score: 0COVID-19 Continues to Result in High Admission, Fatality Rates Among Patients With CLL - 3 year(s) ago
COVID-19 continued to result in high admission and fatality rates among patients with chronic lymphocytic leukemia during the first 13 months of the pandemic, and although risk of severe infection was determined to be independent of age, CLL status, and treatment, being age 75 years or older was revealed to be a significant risk factor for death.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
COVID19 had high fatality rates among pts w/ CLL during the first 13 months of the pandemic, & although risk of severe infection was determined to be independent of age, being 75+ revealed to be a significant risk factor for death @iwCLL #iwCLL2021 #leusm https://t.co/ozbjgzyjbL https://t.co/KVLA5bGxp3
-
-
Mashup Score: 2
Romain Guièze, MD, of Université Clermont Auvergne, Clermont-Ferrand, France, gives an overview on his presentation at iwCLL 2021, on the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Shenmiao Yang, MD, Peking University Institute of Hematology, Peking University People’s Hospital, Peking, China, discusses how genetics might explain the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0VJHemOnc – The video journal of hematological oncology - 3 year(s) ago
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve the awareness and understanding of hematological cancers
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 3Highlights from iwCLL 2021 - 3 year(s) ago
The management of chronic lymphocytic leukemia (CLL) has evolved drastically over the last few years, with the introduction of novel…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
Treatment with acalabrutinib as monotherapy or in combination with obinutuzumab improved quality-adjusted survival compared with chlorambucil plus obinutuzumab in patients with treatment-naïve chronic lymphocytic leukemia. @iwCLL #iwCLL2021 #leusm https://t.co/so2xf7mRun